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OBJECTIVES The goal of this study was to determine the role of lectin-like oxidized low-density
lipoprotein receptors (LOX-1), a recently identified oxidized low-density lipoprotein (ox-
LDL) receptor, in ischemia-reperfusion injury to the heart.
BACKGROUND Reactive oxygen species (ROS) released during ischemia-reperfusion oxidize low-density
lipoproteins; LOX-1 is upregulated by ox-LDL and ROS, and is involved in cell injury.
METHODS Anesthetized rats were subjected to left coronary artery ligation for 60 min (n  10, ischemia
group), or ischemia followed by 60 min of reperfusion (n  30, ischemia-reperfusion group).
Rats in the latter group were treated with saline, the LOX-1 blocking antibody JXT21 (10
mg/kg), or nonspecific anti-goat immunoglobulin G (IgG) (10 mg/kg). Ten other rats
underwent thoracotomy without coronary ligation (sham control).
RESULTS Ischemia-reperfusion was associated with an increase in LOX-1 expression, lipid peroxidation
and apoptosis, a large infarct area, and a decrease in left ventricular function (all, p  0.01 vs.
sham control and ischemia alone groups). Treatment of rats with LOX-1 antibody prevented
ischemia-reperfusion–induced upregulation of LOX-1. Importantly, the LOX-1 antibody
reduced apoptosis by 48%, lipid peroxidation by 39%, and myocardial infarct size by 45%, and
improved left ventricular function (first derivative of pressure measured over time: 47% to
18%, p  0.01). Nonspecific IgG had no effect.
CONCLUSIONS Lectin-like oxidized low-density lipoprotein receptors are upregulated during myocardial
ischemia-reperfusion, and appear to be associated with apoptosis, necrosis, and left ventricular
functional deterioration. (J Am Coll Cardiol 2003;41:1048–55) © 2003 by the American
College of Cardiology Foundation
Myocardial ischemia-reperfusion represents a clinically rel-
evant problem associated with thrombolysis, percutaneous
coronary interventions, and coronary bypass surgery. Injury
to myocardium during ischemia-reperfusion includes car-
diac contractile dysfunction (1), arrhythmias (2), and irre-
versible myocyte damage (3). Reperfusion injury is thought
to be associated with generation of reactive oxygen species
(ROS) (4), which overwhelm the scavenging capacities of
antioxidant enzymes and result in oxidation of lipids and
oxidative damage to the myocardium. Recent studies sug-
gest that plasma levels of oxidized low-density lipoproteins
(ox-LDL) are markedly elevated in patients with acute
coronary syndromes, and the ischemic-reperfused tissues
contain large amounts of ox-LDL (5,6).
Oxidized low-density lipoproteins and ROS trigger apo-
ptosis that is mediated by the activation of the caspase
cascade and results in the cleavage of protein substrates and
fragmentation of deoxyribonucleic acid. Apoptosis is recog-
nized as a major mechanism of cell death during ischemia-
reperfusion (3,4), although the relative contribution of
necrosis and apoptosis to total cardiac cell loss remains
controversial. Nonetheless, the extent of myocardial injury
during ischemia-reperfusion correlates with the degree of
myocardial dysfunction (7,8).
Recent studies show that LOX-1, a newly described
lectin-like receptor for ox-LDL, plays an important role in
cell injury and phagocytosis of dead cells (9–11); LOX-1
activation also mediates adhesion of inflammatory cells to
the activated endothelium by facilitating expression of
adhesion molecules (10). Expression of LOX-1 gene is
upregulated by ox-LDL, angiotensin II, endothelin, ROS,
inflammatory cytokines, and shear stress (12–16). Angio-
tensin II, endothelin, ROS, and proinflammatory cytokines
are considered major mediators of injury during ischemia-
reperfusion.
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The present study was designed to explore the expression
of LOX-1 and its role in apoptosis, necrosis, and cardiac
dysfunction during myocardial ischemia-reperfusion.
METHODS
Animal model. Male Sprague-Dawley rats (250 to 300 g)
were anesthetized with pentobarbital (30 mg/kg, given
intraperitoneally), intubated, and ventilated. A left thora-
cotomy was performed, and the left coronary artery identi-
fied and ligated with 6-0 silk suture 4 mm from its origin
with a slipknot. Total ischemia was confirmed by myocar-
dial blanching and electrocardiographic evidence of injury.
Ischemia was continued for 1 h, when in some animals the
ligature was removed and the blood flow allowed to resume
(reperfusion) for 1 h. Other rats were subjected to thora-
cotomy without left coronary artery ligation (sham control
group). Rats subjected to ischemia-reperfusion were
given saline, the anti-rat LOX-1 blocking antibody (JTX21)
or the anti-goat nonspecific immunoglobulin G (IgG)
(10 mg/kg) intravenously. Preliminary studies showed that
LOX-1 antibody exerted its maximal effects on cardiac
protection when 50% of the total dose was given just before
ischemia and the remaining 50% during ischemia and
reperfusion.
Materials. Anti-rat LOX-1 monoclonal antibody was gen-
erated by immunizing Balb/c mice with rat LOX-1-CHO
cells stably expressing rat LOX-1. Hybridoma from the
splenocytes was prepared by standard procedures, and
screened by cell-surface immunobinding to rat LOX-1-
CHO cells. The LOX-1 antibody (JTX21) was selected
based on its ability to block ox-LDL binding and uptake in
rat LOX-1-expressing cells as described previously (17,18).
Immunostaining kit was purchased from Santa Cruz Bio-
technology (Santa Cruz, California). Caspase-3 fluorescent
protease and terminal dUTP nick end-labeling (TUNEL)
kits were purchased from Promega (Madison, Michigan).
Other reagents were purchased from Sigma (St. Louis,
Missouri).
Northern blot assay. Total ribonucleic acid (15 g) from
the core of left coronary artery-supplied myocardium was
fractionated on a formaldehyde-denatured 1.2%-agarose gel
and transferred to a nylon membrane filter. After prehy-
bridization, the filter was hybridized with the 32P-labelled
rat LOX-1 probe (106 cpm/ml) in a solution containing
50% formamide at 42°C for 16 h. The membrane was
washed twice in 2SSC (0.3 M sodium citrate and 3 M
sodium chloride) containing 0.1% (w/v) SDS (sodium
dodecyl sulfate) at room temperature, followed by washes in
0.16SSC containing 0.1% (w/v) SDS at 50°C for 15 min.
The filter was exposed to Kodak film with an intensifying
screen at 80°C. The band density was quantified by
Gel-Scan-it software (Sigma); LOX-1 expression was stan-
dardized with that of housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (12).
Western blot assay. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis was performed on 10% separation gels
with a 6% stacking gel. Proteins were transferred to nitro-
cellulose membrane (Bio-Rad, California). Blots were in-
cubated with antibody to LOX-1 with 1:500 dilution at 4°C
overnight. Blots were incubated with horseradish peroxi-
dase—conjugated secondary antibody—and signal was de-
tected with enhanced chemiluminescence (Amersham Life
Science, New Jersey) (10,12).
Immunostaining. Details of immunostaining have been
published earlier (19). In brief, 5 m-thick sections from
myocardial tissues taken from the core of left coronary
artery-supplied regions were incubated with primary anti-
body to LOX-1 overnight at 4°C, rinsed in phosphate-
buffered saline, and incubated with anti-mouse IgG conju-
gated to tetramethylrhodamine.
To localize the expression of LOX-1, myocardial sections
were subjected to double immunostaining. EnVision dou-
blestain system was purchased from DAKO Co. (Carpin-
teria, California). The first stain was anti-rat LOX-1
antibody shown as the dark-brown color. Sections were
subsequently incubated with anti-rat desmin (rat cardiac
myocytes). The red color reflects the secondary target
antigen.
Caspase-3 activity assay. Homogenate of myocardial tis-
sues from the ischemic (or the ischemic-reperfused) areas
was prepared. Protein concentration of the homogenate was
adjusted to 1 to 2 g/l. Myocardial tissue extracts (50 g)
were incubated with 245 l of reaction buffer containing
80 l of caspase buffer, 5 M of Me2SO, and 10 mM DTT
for 30 min at 30°C. Thereafter, the fluorescence substrate
Ac-DEVD-AMC was added at a final concentration of
50 M. The reaction mixtures were incubated for 2 h at
30°C. Cleavage of fluorogenic substrate was quantitated by
using a fluorescence spectrophotometer at 400/505 nm (20).
TUNEL staining. The TUNEL staining was performed
as described earlier (21) with propidium iodide nuclear
counterstaining. Negative controls were cells without ter-
minal deoxynucleotidyl transferase. Positive controls were
samples pretreated with DNase I. Nuclei were counted in 8
to 10 microscopic high power fields (40) in the core of the
ischemic region of the heart supplied by the left coronary
artery. Virtually all TUNEL-positive nuclei were confined
to a well-circumscribed area within the ischemic zone;
TUNEL-positive nuclei from this region were randomly
counted in 8 to 10 high power fields in each slide.
Abbreviations and Acronyms
IgG  immunoglobulin G
LOX-1  lectin-like oxidized low-density lipoprotein
receptors
mRNA  messenger ribonucleic acid
ox-LDL  oxidized low-density lipoprotein
ROS  reactive oxygen species
TTC  triphenyl tetrazolium chloride
TUNEL  terminal dUTP nick end-labeling
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Measurement of lipid peroxidation. Myocardial malondi-
aldehyde was measured using the thiobarbituric acid reactive
substances assay, as described previously (22).
Determination of infarct size. At the end of ischemia-
reperfusion, the heart was quickly removed and mounted on
a Langendorff apparatus (Astra-Med, West Warwick,
Rhode Island), and flushed with saline for 60 s. The left
coronary artery was re-ligated, and Evan’s Blue dye was
infused into the perfusate to mark the area at risk. The heart
was then cut into six transverse slices. The slices were
incubated in 1% triphenyl tetrazolium chloride (TTC) in
pH 7.4 buffer for 15 min. For each section, the area-at-risk
(Evan’s blue-negative area) and infarct area (TTC-negative
area) were traced and measured by planimetry. Infarct size
was calculated as: TTC-positive area divided by the area at
risk for that slice. Infarct size in all six slices was then
calculated and averaged (23).
Hemodynamic measurements. Left ventricular pressure
was monitored using a fluid-filled catheter (PE-50) inserted
through the right carotid artery and advanced to the left
ventricle. Left ventricular contractility (dP/dt) and arterial
pressure were recorded on a Astra-Med four-channel phys-
ical recorder throughout the procedure.
Data analysis. All data represent mean of at least eight
independently performed experiments. Data are presented
as mean  SD. Data were analyzed by analysis of variance,
followed by a Bonferroni correction. A p value of0.05 was
considered to be statistically significant.
RESULTS
LOX-1 expression during myocardial ischemia-reperfusion.
The expression of LOX-1 (messenger ribonucleic acid
[mRNA] and protein) was markedly increased in the
ischemia-reperfusion group compared with that in the sham
control group (p  0.01, n  8). Ischemia alone did not
increase the expression of LOX-1. Administration of the
LOX-1 antibody before ischemia attenuated the upregula-
tion of LOX-1 (p  0.01 vs. ischemia-reperfusion group
treated with saline). Administration of nonspecific IgG had
no effect on LOX-1 expression (Fig. 1).
The expression of LOX-1 was confirmed by immuno-
staining, which showed an increase in LOX-1 expression in
the core of the ischemic-reperfused area. Positive immuno-
reactivity for LOX-1 was identified mainly in the endocar-
dium and the subendocardial regions of myocardium. Use
of the antibody reduced LOX-1 expression, whereas the
nonspecific IgG had no effect. A representative example of
LOX-1 expression in each group of rats is shown in
Figure 2.
To identify the location of LOX-1 in the myocardial
sections, double immunostaining was performed. As shown
in Figure 3, LOX upregulation was identified mainly in the
cardiac myocytes.
Ischemia-reperfusion and apoptosis. Ischemia alone only
slightly increased the number of apoptotic cells. In contrast,
apoptotic cells were clearly evident in the ischemic-
reperfused regions in saline-treated rats. Administration of
LOX-1 antibody reduced the number of apoptotic cells
despite ischemia-reperfusion (p  0.01 vs. saline-treated
group). The administration of nonspecific IgG had no effect
on the number of apoptotic cells. Figure 4 shows represen-
tative examples of the presence of apoptotic cells in the
ischemic-reperfused area in each group, as well as a sum-
mary of the data on the number of apoptotic cells in each
group.
Ischemia-reperfusion–induced apoptosis was confirmed
Figure 1. Expression of lectin-like oxidized low-density lipoprotein receptor (LOX-1) messenger ribonucleic acid (mRNA) and protein after
ischemia-reperfusion (I-R); LOX-1 protein and mRNA were determined by Western and Northern blots, respectively. The expression of LOX-1 was
markedly increased in the saline-treated rats subjected to I-R. Ischemia alone did not increase the expression of LOX-1. Administration of blocking
antibody to rat LOX-1 attenuated the expression of LOX-1 despite I-R. In contrast, administration of nonspecific immunoglobulin G (IgG) had no effect.
Density of LOX-1 mRNA band was normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band density. Each band density of LOX-1
protein was normalized with that in the sham control rat heart. Left panel shows representative examples; right panel is the summary of data (mean 
SD) from eight separate experiments.
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by the measurement of caspase-3 activity, which was con-
sistently increased in the hearts from saline-treated rats
subjected to ischemia-reperfusion (p  0.01 vs. sham
control group). Ischemia alone had no effect on caspase-3
activity. Administration of the LOX-1 antibody reduced
caspase-3 activity despite ischemia-reperfusion (p 0.01 vs.
saline group), whereas nonspecific IgG had no effect
(Fig. 4).
Ischemia-reperfusion and lipid peroxidation. The mal-
ondialdehyde levels were markedly increased in the hearts
from saline-treated rats subjected to ischemia-reperfusion
(p  0.01 vs. sham control group, n  10). Ischemia alone
did not affect malondialdehyde levels. Administration of the
antibody to LOX-1 reduced myocardial malondialdehyde
levels (p  0.01 vs. saline group, n  10), whereas
nonspecific IgG had no effect (Fig. 5).
Ischemia-reperfusion and infarct size. Hearts from sham
control group did not show any TTC-positive areas. The
area-at-risk in the ischemia alone group and the three
ischemia-reperfusion groups was similar. There was exten-
sive TTC positivity in the hearts from the saline-treated
ischemia-reperfusion group (33  5% vs. 22  4% at
area-at-risk in ischemia alone group, p  0.01, n  10).
Treatment of rats with the LOX-1 antibody decreased
infarct size (18  6% vs. 33  5%, p  0.01, n  10). The
use of nonspecific IgG had no effect (Fig. 6).
Ischemia-reperfusion and cardiac dysfunction. As shown
in Figure 7, dP/dt and mean arterial pressure were signifi-
cantly decreased during ischemia. Reperfusion caused a
further decrease in dP/dt, arterial pressure, and heart rate
(p  0.01 vs. sham control group or ischemia alone group,
n  10). Administration of the LOX-1 antibody signifi-
cantly improved dP/dt, arterial pressure, and heart rate
despite ischemia-reperfusion (all, p  0.01 vs. saline group,
n  10). The administration of nonspecific IgG had no
effect.
DISCUSSION
We show that LOX-1 expression is upregulated in the
ischemic-reperfused myocardium. The upregulation of
LOX-1 contributes to reperfusion injury as evident from
the data on the use of LOX-1 antibody, which decreased
infarct size and improved cardiac function. The antibody to
LOX-1 also reduced ischemia-reperfusion–mediated apo-
ptosis and lipid peroxidation. Importantly, nonspecific IgG
had no protective effect against ischemia-reperfusion injury.
Release of ROS during ischemia-reperfusion and LOX-1
expression. Reactive oxygen species are released during
reperfusion and induce peroxidation of lipid bilayer of cell
membrane, injure endothelial cells, denature constitutive
nitric oxide, and promote migration and accumulation of
inflammatory cells in the ischemic-reperfused areas (7,8).
Inhibition of ROS has been shown to reduce the phenom-
enon of reperfusion injury and improve cardiac dysfunction
Figure 2. Expression of lectin-like oxidized low-density lipoprotein recep-
tors (LOX-1) in the ischemic-reperfused (I-R) areas was confirmed by
immunostaining. Positive immunoreactivity for LOX-1 was identified
mainly in the endocardium and the subendocardial areas of the myocar-
dium. Again, the use of LOX-1 antibody (Ab-LOX-1) reduced LOX-1
staining after I-R, while nonspecific immunoglobulin G (IgG) had no
effect.
Figure 3. Location of lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression in rat cardiac myocytes was confirmed by double
immunostaining (brown color LOX-1; red color anti-desmin for rat cardiac myocytes); LOX-1 expression was primarily within the cardiac myocytes.
Left panel is a negative control specimen, middle panel is myocyte staining in sham control heart, and right panel is double staining showing LOX-1
expression in myocytes. I-R  ischemia-reperfusion.
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(7,24). Reactive oxygen species oxidize lipids, and result in
increased ox-LDL levels. Plasma levels of ox-LDL have
been shown to be elevated in patients with acute coronary
syndromes (5). Tsutsui et al. (25) have suggested that
ox-LDL can be used as a prognostic predictor in patients
with chronic congestive heart failure. Another study (6)
found that ox-LDL is localized in the myocardium of
patients with ischemia; ox-LDL was present in large
amounts in the left and right ventricles of these patients.
Positive immunoreactivity for ox-LDL was mainly identi-
fied in the endocardium and the subendocardial areas of the
left ventricle.
We observed that a brief period of ischemia followed by
a brief period of reperfusion, but not ischemia alone,
upregulated LOX-1, which suggests that reperfusion is
necessary for LOX-1 upregulation. In fact, we observed that
malondialdehyde levels were higher in the ischemic-
reperfused myocardium compared with those in sham con-
Figure 4. Effect of lectin-like oxidized low-density lipoprotein receptor (LOX-1) antibody (Ab-LOX-1) on apoptosis and caspase-3 expression in response
to ischemia-reperfusion (I-R). The number of apoptotic cells was increased in the I-R group (saline-treated rats) compared with the sham control group.
Use of the LOX-1 antibody reduced the number of apoptotic cells. Nonspecific anti-goat immunoglobulin G (IgG) had no effect. Left top panel shows
representative examples of apoptotic cells (green color). Left bottom panel is summary of data on the number of apoptotic cells from 10 separate
experiments. Caspase-3 activity in the myocardium was also increased in the I-R group (saline-treated rats) compared with the sham control group. Use
of the LOX-1 antibody reduced caspase-3 activity. Nonspecific IgG had no effect (right panel).
Figure 5. Lectin-like oxidized low-density lipoprotein receptors (LOX-1)
expression and lipid peroxidation. Lipid peroxidation was determined by
the measurement of malondialdehyde (MDA). Myocardial MDA levels
were markedly higher in the saline-treated rats subjected to ischemia-
reperfusion (I-R); LOX-1 antibody (Ab-LOX-1) reduced MDA levels,
while the nonspecific immunoglobulin G (IgG) had no effect. The data is
mean ( SD) of values from 10 separate experiments.
Figure 6. Lectin-like oxidized low-density lipoprotein receptor (LOX-1)
expression and infarct size. The sham control group did not show any
necrotic area. The risk area in all ischemia-reperfusion (I-R) groups
(saline-treated, LOX-1 antibody [Ab-LOX-1]-treated, and nonspecific
immunoglobulin G [IgG]-treated) was similar. Infarct size was smaller in
the LOX-1 antibody-treated rats compared with that in the saline-treated
or the nonspecific IgG-treated rats. The data on infarct size (mean  SD)
is from 10 separate experiments. AAR  area at risk; LV  left ventricle.
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trol and the ischemia alone groups, indicating that the
release of ROS during reperfusion oxidizes lipids. We
speculate that ROS and ox-LDL both upregulate the
expression of LOX-1 and activate LOX-1 receptors. Acti-
vation of LOX-1 would further increase ROS generation
and lipid oxidation. This positive feedback amplifies the
interaction between ROS and ox-LDL resulting in cell
death and cardiac dysfunction. The role of LOX-1 upregu-
lation in this process became clear from experiments in
which treatment of rats with a specific LOX-1 blocking
antibody decreased LOX-1 expression and, subsequently,
the extent of myocardial injury.
LOX-1 expression and apoptosis during ischemia-
reperfusion. Apoptosis is a critical cellular event involved
in the pathogenesis of myocardial ischemia-reperfusion
injury (3,26–31). Expression of a number of genes, such as
Fas and Bcl2, is altered during reperfusion and leads to
apoptosis (3,26–31). Caspases are cysteine proteinases that
have been shown to be specifically involved in the initiation
and execution phases of apoptosis (26–28). Scarabelli et al.
(28) found that activation of caspase-9 occurs primarily in
endothelial cells, while caspase-8 activation is present in rat
cardiomyocytes exposed to ischemia-reperfusion. As evi-
dence for the pathogenic role of caspase-9, addition of a
specific caspase-9 inhibitor to the perfusate before ischemia
prevented endothelial apoptosis, whereas infusion of a
specific caspase-8 inhibitor affected only myocyte apoptosis.
Both caspase-8 and caspase-9 activate caspase-3 and then
cleave vital cellular proteins. Experimental studies have
indeed shown that the activation of caspase-3 is an impor-
tant process in myocardial reperfusion injury (29). Other
studies show that oxidative stress plays an important role in
apoptosis (30,31). For example, Maulik et al. (30) found
that apoptotic cells were markedly increased in isolated
perfused rat hearts subjected to 15 min of ischemia followed
by 60 to 120 min of reperfusion. The number of apoptotic
cells in the myocardium was eliminated by preperfusing the
hearts in the presence of ebselen, which removed the
oxidative stress. Minamino et al. (31) also found that
oxidative stress induces apoptosis of cardiac myocytes and
that inhibition of oxidative stress inhibits apoptosis.
Oxidized low-density lipoprotein, a potent oxidative
stress factor, induces apoptosis in endothelial cells (22),
smooth muscle cells (32), and monocytes/macrophages (33).
We (21) have recently shown that LOX-1 activation plays a
critical role in ox-LDL-induced apoptosis of human coro-
nary artery endothelial cells because inhibition of LOX-1
expression by a specific antisense to LOX-1 mRNA signif-
icantly decreased ox-LDL-induced apoptosis. Iwai-Kanai et
al. (34) recently observed that overexpression of LOX-1 in
cardiac myocytes induces apoptosis through activation of
the p38 mitogen-activated protein kinase pathway. In the
present study, we show that reperfusion after total ischemia
markedly increases the activity of caspase-3 and the number
of apoptotic cells in the region supplied by the left coronary
artery. Ischemia alone has no significant effect on the degree
of apoptosis. We suggest that LOX-1 expression and
activation are related, at least in part, to the development of
apoptosis because the LOX-1 antibody JXT21 reduced
caspase-3 activation and the number of apoptotic myocytes.
In contrast with this effect of LOX-1 antibody, the non-
specific IgG antibody had no effect.
Figure 7. Lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression and cardiac dysfunction during ischemia-reperfusion (I-R) and dP/dt
and mean arterial blood pressure (MABP) during ischemia. Reperfusion further reduced dP/dt, MABP, and heart rate. Administration of LOX-1 antibody
significantly improved dP/dt, MABP, and heart rate, whereas nonspecific immunoglobulin G (IgG) had no effect.
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Some investigators (35,36) have suggested that oncosis
may play a more important role than apoptosis in the
ischemia-reperfusion injury to the heart. However, addi-
tional data are needed to justify this statement because
experimental model and protocol have varied in different
studies. In the present study, we cannot exclude oncosis-
mediated ischemia-reperfusion injury. We found an in-
crease in apoptosis in the ischemic-reperfused regions, and
some of the TUNEL-positive cells may have been under-
going oncosis.
LOX-1, infarct size, and cardiac dysfunction after ischemia-
reperfusion. It is generally recognized that reperfusion
therapy prolongs survival in patients with acute myocardial
infarction. However, reperfusion also enhances myocardial
injury beyond that caused by ischemia, perhaps related to
the release of cytokines, ROS, calcium overload, and leu-
kocyte recruitment (1–3,7,8,24). Studies in isolated perfused
rat heart have demonstrated that ox-LDL induces ultra-
structural abnormalities and decreases myocardial contrac-
tile function.
Reperfusion injury occurs in the early hours after reper-
fusion, especially the first hour (1–3,7,8,24). Generation of
ROS and ox-LDL and release of certain cytokines during
ischemia-reperfusion cause cell injury through different
pathways, and induce injury in a synergistic fashion. Our
study shows an increase in myocardial lipid peroxidation
and LOX-1 expression in the reperfused regions. Evidence
for the important role of LOX-1 in reperfused injury came
from the use of LOX-1 blocking antibody, which decreased
infarct size by about 45%. The salutary effect of LOX-1
antibody may be secondary to blockade of LOX-1 activation
and its interaction with other injurious stimuli.
Size of the infarcted tissue is an important determinant of
left ventricular function, and therapies that decrease infarct
size generally improve cardiac function. Indeed, LOX-1
blocking antibody, when used before the onset of ischemia,
significantly reduced cardiac dysfunction. This beneficial
effect may relate to the inhibitory effect of LOX-1 antibody
on generation of ROS, ox-LDL, and apoptosis.
Conclusions. This study shows that myocardial ischemia-
reperfusion increases LOX-1 expression that contributes to
reperfusion injury through an increase in apoptosis, lipid
peroxidation, infarct size, and cardiac dysfunction. The
contribution of LOX-1 in reperfusion injury became evident
from experiments in which blockade of LOX-1 activation
reduced myocardial ischemia-reperfusion injury. Notably,
LOX-1 antibody only reduced, and not abolished,
ischemia-reperfusion injury, suggesting that LOX-1 expres-
sion is one of many pathways involved in the genesis of
reperfusion injury.
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